KDR and neoplasm: The pivotal role played by VEGF-A in activating tumor angiogenesis prompted that the majority of antiangiogenic therapies were designed to neutralize the activation of endothelial cells by this angiogenic factor, either by directly blocking VEGF-A or by inhibiting the activation of VEGFR2 [36] (Figure 3).